Danazol Treatment for Telomere Diseases.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 71 citations in OpenAlex.

1. Dyskerin dysfunction in cancer development: from telomere dysregulation to immune deficiency.American journal of cancer research · 2026
   Review
2. Extracellular vesicles for delivery of functional telomerase.Cell communication and signaling : CCS · 2025
   Article
3. High-throughput telomere length measurement at nucleotide resolution using the PacBio high fidelity sequencing platform.Nature communications · 2023
   Article
4. Telomere Attrition and Clonal Hematopoiesis of Indeterminate Potential in Cardiovascular Disease.International journal of molecular sciences · 2021
   Review
5. p53 Activation in Genetic Disorders: Different Routes to the Same Destination.International journal of molecular sciences · 2021
   Review
6. An update on the biology and management of dyskeratosis congenita and related telomere biology disorders.Expert review of hematology · 2019
   Review
7. Correlation of human telomerase reverse transcriptase single nucleotide polymorphisms with in vitro fertilisation outcomes.Journal of assisted reproduction and genetics · 2019
   Article
8. Evaluation and Management of Hematopoietic Failure in Dyskeratosis Congenita.Hematology/oncology clinics of North America · 2018
   Review
9. Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita.Blood advances · 2018
   Observational
10. Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions.International journal of molecular sciences · 2017
    Review

Corrections and comments

• Commented on by
  Danazol Treatment for Telomere Diseases.2016
• Comment on
  Danazol Treatment for Telomere Diseases.2016

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as